Intelligent Bio Solutions Reports Q4 16% Revenue Growth, Expands US Market.

• Intelligent Bio Solutions Inc. (INBS) reported 16% QoQ and YoY revenue growth in Q4 • Growth driven by increased demand for drug testing cartridges • Company advanced efforts to secure FDA 510(k) clearance for US market expansion • Expansion in international markets with 450+ accounts across 24 countries

Intelligent Bio Solutions Inc. (INBS), a medical technology company specializing in rapid, non-invasive drug testing solutions, has reported robust financial performance for the fiscal fourth quarter and full-year ended June 30, 2025. The company achieved sequential and year-on-year revenue growth of 16%, driven primarily by increased demand for its drug testing cartridges [1].

The Q4 revenue of $843,884 marked a 16% year-on-year increase from the previous fiscal fourth quarter and a 16% quarter-on-quarter increase from the fiscal third quarter. Revenue from cartridge sales, the company's highest-margin revenue stream, grew by 9% quarter-on-quarter and 24% year-on-year, contributing significantly to the overall growth [1].

INBS secured 115 new accounts in 2025, expanding its customer base to over 450 active accounts across 24 countries. The company continues to expand its commercial presence internationally, with active customer bases in key markets such as the UK, Europe, and the Middle East [1].

The company's efforts to secure FDA 510(k) clearance for its opiate test system for codeine in the U.S. are ongoing. INBS has made significant strides in advancing its regulatory strategy, including increased engagement with regulatory consultants and the generation of new scientific and clinical data to support its submission [1].

In addition to its U.S. market expansion efforts, INBS is actively scoping regulatory opportunities in Canada, Indonesia, and the Philippines. The company is also conducting micro-level analysis to assess regulatory barriers, relevant drug testing legislation, and regional industry concentrations in the U.S. market [1].

Operational efficiencies and business localization efforts have strengthened the company's fundamentals. The multilingual upgrade of the Intelligent Fingerprinting Drug Screening System now supports Arabic and Latin American Spanish, and regionally localized websites have been launched in Italian, Spanish, and Arabic [1].

Intelligent Bio Solutions Inc. has also implemented a new accounting system to enhance internal controls and improve financial reporting accuracy. The addition of a sixth U.S. patent to its intellectual property portfolio reinforces the company's long-term defensibility [1].

Looking ahead, INBS is focused on accelerating growth, advancing operational excellence, and expanding beyond Forensic Use Only settings in the U.S. The company's trajectory reflects the growing traction of its testing solutions in key markets, providing investors with confidence in its future prospects [1].

References:
[1] https://www.marketscreener.com/news/intelligent-bio-solutions-reports-fiscal-2025-fourth-quarter-and-full-year-results-highlighting-pro-ce7c51dedf89f725